<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476084</url>
  </required_header>
  <id_info>
    <org_study_id>149600</org_study_id>
    <nct_id>NCT02476084</nct_id>
  </id_info>
  <brief_title>Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients</brief_title>
  <acronym>BMUS</acronym>
  <official_title>Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients: a Pilot Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the kinetics of change in quantitative measures of&#xD;
      joint inflammation by state of the art power Doppler vascular imaging and to identify&#xD;
      biomarkers in biological samples (synovial biopsies, DNA, RNA, PBMC, serum, plasma, urine and&#xD;
      stool samples) from parallel cohorts of RA patients undergoing different treatments. This&#xD;
      will be achieved implementing MSUS assessments, standard laboratories techniques (such as&#xD;
      ELISAs, gene profiling, transcriptome analysis etc.) and the novel CyTOF™ technology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in synovial thickness and vascularity using a limited joint set musculoskeletal ultrasound examination in Rheumatoid Arthritis.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the distribution of cell populations in biological samples from Rheumatoid Arthritis patients using CyTOF.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gene expression in biological samples from Rheumatoid Arthritis patients using gene profiling.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokines' concentration in biological samples from Rheumatoid Arthritis patients using ELISA and transcriptome analysis.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Conventional synthetic DMARD naïve</arm_group_label>
    <description>Naive RA patients commencing Methotrexate and Hydroxychloroquine.&#xD;
Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMARD-IR: anti-TNF</arm_group_label>
    <description>Conventional synthetic DMARD inadequate responders commencing Anti-TNF&#xD;
Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMARD-IR: anti-IL6</arm_group_label>
    <description>Conventional synthetic DMARD inadequate responders commencing anti-IL6&#xD;
Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMARD-IR: anti-CTLA-4</arm_group_label>
    <description>Conventional synthetic DMARD inadequate responders commencing anti-CTLA-4&#xD;
Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMARD-IR: anti-CD20</arm_group_label>
    <description>Conventional synthetic DMARD inadequate responders commencing anti-CD20&#xD;
Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Musculoskeletal Ultrasound Imaging</intervention_name>
    <description>B-mode and PD musculoskeletal ultrasound examination of selected joints.</description>
    <arm_group_label>Conventional synthetic DMARD naïve</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CD20</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CTLA-4</arm_group_label>
    <arm_group_label>DMARD-IR: anti-IL6</arm_group_label>
    <arm_group_label>DMARD-IR: anti-TNF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Synovial biopsy</intervention_name>
    <description>US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.</description>
    <arm_group_label>Conventional synthetic DMARD naïve</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CD20</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CTLA-4</arm_group_label>
    <arm_group_label>DMARD-IR: anti-IL6</arm_group_label>
    <arm_group_label>DMARD-IR: anti-TNF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological samples collection</intervention_name>
    <description>Draw of research blood samples.</description>
    <arm_group_label>Conventional synthetic DMARD naïve</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CD20</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CTLA-4</arm_group_label>
    <arm_group_label>DMARD-IR: anti-IL6</arm_group_label>
    <arm_group_label>DMARD-IR: anti-TNF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Administration of validated patients' questionnaires.</description>
    <arm_group_label>Conventional synthetic DMARD naïve</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CD20</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CTLA-4</arm_group_label>
    <arm_group_label>DMARD-IR: anti-IL6</arm_group_label>
    <arm_group_label>DMARD-IR: anti-TNF</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and and Biologic samples collected will be processed in the CTU Translational Research&#xD;
      Lab and stored within the Botnar Research Centre adhering to local guidelines on sample&#xD;
      requirements, handling and storage. All biological samples will be available for future&#xD;
      studies for biomarker profiling.&#xD;
&#xD;
      The following blood samples will be drawn in order:&#xD;
&#xD;
        1. Two (10.0ml) K2EDTA tube&#xD;
&#xD;
        2. One (5.0ml) SST tube&#xD;
&#xD;
        3. One (3 ml) Tempus RNA tube&#xD;
&#xD;
        4. One (6 ml) DNA EDTA tube (only during Visit 1)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatoid Arthritis Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written confirmed diagnosis of Rheumatoid Arthritis as per ACR/EULAR 2010 criteria.&#xD;
&#xD;
          -  If patient is on oral corticosteroids, dose must be stable for 6 weeks prior to&#xD;
             baseline visit.&#xD;
&#xD;
          -  Willingness and ability to comply with all the study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any systemic inflammation conditions (other than RA), connective tissue disease or&#xD;
             chronic pain disorders that may interfere with the interpretation of the outcome data.&#xD;
             Examples include psoriatic arthritis, reactive arthritis, gout, systemic lupus&#xD;
             erythematosus (SLE), polymyalgia rheumatic and/or temporal arteritis, Lyme's disease,&#xD;
             fibromyalgia and chronic fatigue syndromes.&#xD;
&#xD;
          -  Major surgery planned within 8 weeks prior to screening or planned surgery throughout&#xD;
             the study period.&#xD;
&#xD;
          -  Treatment with any investigational agent ≤ 4 weeks prior to baseline (or 5 ≤&#xD;
             half-lives of the investigational drug, whichever is the longer).&#xD;
&#xD;
          -  Intramuscular/intra-articular glucocorticoids for 6 weeks prior to baseline visit.&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  Septic arthritis within a native joint within the last 12 months.&#xD;
&#xD;
          -  Sepsis of a prosthetic joint within 12 months or indefinitely if the joint remains in&#xD;
             situ.&#xD;
&#xD;
          -  Known HIV or hepatitis B/C infection.&#xD;
&#xD;
          -  Latent TB infection unless they have completed adequate antibiotic prophylaxis.&#xD;
&#xD;
          -  Malignancy (other than basal cell carcinoma) within the last 10 years.&#xD;
&#xD;
          -  New York Heart Association (NYHA) grade 3 or 4 congestive cardiac failure.&#xD;
&#xD;
          -  Demyelinating disease.&#xD;
&#xD;
          -  Presence of a transplanted organ (with the exception of a corneal transplant &gt; 3&#xD;
             months prior to screening).&#xD;
&#xD;
          -  Known recent substance abuse (drug or alcohol).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter C Taylor, MA, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kennedy Institute of Rheumatology, University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuffield Orthopaedic Centre</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

